---
id: encephalitis_086
category: clinical_syndromes
tags: [encephalitis, HSV-encephalitis, acyclovir, MRI-temporal-lobe, CSF-PCR]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Encephalitis

**Q:** What is the diagnostic approach, empiric treatment, and management of viral encephalitis, with focus on HSV encephalitis?

**A:**

**Definition:**
- **Encephalitis:** Inflammation of brain parenchyma with **altered mental status** or **neurologic dysfunction**
- **Meningoencephalitis:** Combined meningitis + encephalitis

**Key Point:** **Encephalitis = brain dysfunction** (altered mental status, seizures, focal deficits), **Meningitis = meningeal inflammation** (headache, neck stiffness)

---

## EPIDEMIOLOGY

**Incidence:**
- **3.5-7.4 cases per 100,000** annually
- **Etiology identified:** Only 40-60% of cases

**Mortality:**
- **Untreated HSV encephalitis:** 70%
- **Treated HSV encephalitis:** 20-30%
- **Other viral:** 5-20%

---

## CLINICAL PRESENTATION

**Classic Features:**

**1. Altered Mental Status (REQUIRED FOR DIAGNOSIS):**
- **Confusion, disorientation**
- **Personality changes**
- **Decreased level of consciousness** (lethargy → coma)

**2. Fever:**
- Present in 90%

**3. Seizures:**
- **30-50%** (focal or generalized)
- **Status epilepticus** (10-20%)

**4. Focal Neurologic Deficits:**
- **Aphasia** (temporal lobe - HSV)
- **Hemiparesis**
- **Ataxia** (cerebellum - VZV)
- **Cranial nerve palsies**

**5. Behavioral Changes:**
- **Bizarre behavior, hallucinations** (especially HSV - temporal lobe involvement)

**Key Point:** **Encephalitis = altered mental status + fever** (vs meningitis = headache + neck stiffness WITHOUT altered mental status)

---

## ETIOLOGY

---

### **1. Herpes Simplex Virus (HSV-1) - #1 SPORADIC ENCEPHALITIS (10-20% of Cases)**

**Most Common Treatable Cause**

**Pathophysiology:**
- **HSV-1 reactivation** (NOT primary infection) - from trigeminal ganglion
- **Predilection for temporal lobes** (orbitofrontal, medial temporal)

**Clinical Features:**
- **Acute onset** (days)
- **Behavioral changes, hallucinations** (temporal lobe dysfunction)
- **Aphasia** (if dominant temporal lobe)
- **Seizures** (50-70%)
- **Focal findings** (hemiparesis)

**Key Point:** **HSV-1 = temporal lobe encephalitis** (bizarre behavior, seizures, aphasia)

---

### **2. Varicella-Zoster Virus (VZV)**

**Clinical Features:**
- **May occur WITHOUT rash** (zoster sine herpete)
- **Multifocal CNS involvement:** Encephalitis, cerebellitis, myelitis, vasculopathy (stroke)

---

### **3. Enteroviruses**

**Clinical Features:**
- **Summer/fall**
- **Typically meningitis** (mild), but can cause encephalitis
- **Enterovirus 71:** Brainstem encephalitis (hand-foot-mouth disease outbreaks in Asia)

---

### **4. Arboviruses (Geographic, Seasonal)**

**West Nile Virus (WNV) - #1 Arboviral Encephalitis in US:**
- **Summer/fall** (mosquito season)
- **Acute flaccid paralysis** (anterior horn cell - polio-like)
- **Elderly at higher risk**

**Eastern Equine Encephalitis (EEE):**
- **East Coast US**
- **Most severe arboviral encephalitis** (mortality 30-50%)

**Other Arboviruses:**
- **St. Louis encephalitis** (US)
- **La Crosse virus** (pediatric, Midwest US)
- **Japanese encephalitis** (Asia - vaccine-preventable)
- **Tick-borne encephalitis** (Europe, Asia)

---

### **5. Rabies**

**Transmission:**
- **Animal bite** (bat, raccoon, skunk, dog)

**Clinical Features:**
- **Hydrophobia** (fear of water - pathognomonic)
- **Aerophobia** (fear of air on face)
- **Furious rabies:** Agitation, hyperactivity
- **Paralytic rabies:** Ascending paralysis (Guillain-Barré-like)

**Prognosis:**
- **100% fatal** once symptoms develop (unless post-exposure prophylaxis given before symptoms)

---

### **6. HIV**

**Acute HIV Encephalitis:**
- **Acute retroviral syndrome** (primary HIV infection)

**Chronic HIV Encephalitis:**
- **HIV-associated dementia** (advanced HIV, CD4 <200)

---

### **7. Mycobacterium tuberculosis (TB)**

**Tuberculous Meningoencephalitis:**
- **Subacute** (weeks)
- **Basilar meningitis** (cranial nerve palsies)
- **Tuberculomas** (mass lesions)

---

### **8. Autoimmune/Paraneoplastic Encephalitis**

**Anti-NMDA Receptor Encephalitis:**
- **Young women** (ovarian teratoma)
- **Psychiatric symptoms** → Seizures → Movement disorder (orofacial dyskinesias) → Coma
- **CSF:** Lymphocytic pleocytosis, oligoclonal bands
- **Diagnosis:** Anti-NMDA receptor antibodies (CSF, serum)

**Other Antibodies:**
- **Anti-LGI1, Anti-CASPR2** (voltage-gated potassium channel complex)
- **Anti-Hu, Anti-Yo** (paraneoplastic - small cell lung cancer, ovarian cancer)

---

## DIAGNOSIS

---

### **Step 1: Suspect Encephalitis**

**Clinical Criteria (IDSA 2008):**
- **Altered mental status** (required)
- **Plus ≥2 of:**
  - Fever
  - Seizures
  - Focal neurologic findings
  - CSF pleocytosis
  - Neuroimaging abnormality
  - EEG abnormality

---

### **Step 2: Neuroimaging (MRI Brain With Contrast - PREFERRED)**

**MRI Findings:**

**HSV Encephalitis:**
- **Bilateral temporal lobe hyperintensity** (T2/FLAIR)
- **Hemorrhagic necrosis** (T2*/GRE sequence)
- **Asymmetric involvement** (often unilateral early, then bilateral)

**Key Point:** **MRI temporal lobe involvement = HSV encephalitis** (until proven otherwise)

---

**Other Findings:**

| **Etiology** | **MRI Findings** |
|--------------|------------------|
| **HSV-1** | **Bilateral temporal lobes** (medial, inferior), orbitofrontal cortex |
| **VZV** | Multifocal (gray-white junction), basal ganglia, cerebellum |
| **West Nile Virus** | Thalamus, basal ganglia, brainstem, **spinal cord** (anterior horn - flaccid paralysis) |
| **EEE** | Basal ganglia, thalamus |
| **Rabies** | Basal ganglia, brainstem, hippocampus |
| **Anti-NMDA** | Normal (early) → Diffuse cortical/subcortical hyperintensity (late) |

**Key Point:** **MRI sensitivity for HSV encephalitis:** 90% (within 48h), **CT sensitivity:** Only 50% (MRI preferred)

---

### **Step 3: Lumbar Puncture (CSF Studies)**

**HSV Encephalitis CSF:**

| **Parameter** | **Typical Finding** |
|---------------|---------------------|
| **WBC** | 10-500 cells/μL (lymphocyte predominance)<br>**May be NORMAL in first 24-48h** |
| **RBC** | **Elevated** (hemorrhagic - 10-500 cells/μL) - suggestive of HSV |
| **Glucose** | Normal (>45 mg/dL) |
| **Protein** | Elevated (60-600 mg/dL) |
| **HSV PCR** | **Positive (sensitivity 95%)** |
| **Gram stain/culture** | Negative |

**Key Point:** **RBCs in CSF = hemorrhagic encephalitis = suggestive of HSV** (NOT traumatic tap if consistent across tubes)

---

**HSV PCR:**
- **Sensitivity:** 95% (within first 2 weeks)
- **Specificity:** 98%
- **May be FALSE NEGATIVE** if LP performed <72 hours after symptom onset (repeat LP if high suspicion)

**Key Point:** **HSV PCR = gold standard** (do NOT wait for results to start acyclovir)

---

### **Step 4: Electroencephalography (EEG)**

**HSV Encephalitis EEG:**
- **Periodic lateralized epileptiform discharges (PLEDs)** from temporal lobes
- **Sensitivity:** 80% (but NOT specific)

**Key Point:** **PLEDs on EEG + temporal lobe on MRI = HSV encephalitis**

---

### **Step 5: Additional Testing (Based on Epidemiology)**

**Viral PCR (CSF):**
- **HSV-1/HSV-2 PCR** (always)
- **VZV PCR**
- **Enterovirus PCR** (if summer/fall)
- **West Nile Virus PCR** (if summer/fall, geographic)

**Serology (CSF + Serum):**
- **West Nile Virus IgM** (CSF more sensitive than serum)
- **Arboviruses:** IgM (CSF or serum)

**Autoimmune Encephalitis Panel:**
- **Anti-NMDA receptor antibodies** (CSF preferred over serum)
- **Other antibodies** (anti-LGI1, anti-CASPR2, anti-Hu, anti-Yo)

---

## EMPIRIC TREATMENT

**Key Principle:** **Start acyclovir IMMEDIATELY** (do NOT wait for HSV PCR results)

---

### **Empiric Regimen (Suspected Encephalitis):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Acyclovir** | **10 mg/kg IV q8h** (adjust for renal function) | **14-21 days** |

**Start acyclovir if:**
- **ANY patient with suspected encephalitis** (altered mental status + fever)
- **Do NOT wait for MRI, CSF, or PCR results**

**Key Point:** **"Acyclovir until proven otherwise"** - treat all encephalitis empirically

---

### **When to Add Empiric Antibiotics (Bacterial Meningitis Coverage):**

**Add if uncertain whether meningitis vs encephalitis:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h |
| **PLUS** | |
| **Ceftriaxone** | 2g IV q12h |
| **PLUS** | |
| **Ampicillin** (if age >50 or immunocompromised) | 2g IV q4h |

**Stop antibiotics if:**
- **CSF and imaging consistent with encephalitis** (NOT bacterial meningitis)
- **Bacterial cultures negative**

---

### **When to Add Dexamethasone:**

**NOT routinely recommended for viral encephalitis**

**Consider if:**
- **Uncertain bacterial meningitis vs encephalitis**
- **Severe cerebral edema** (consult neurology/neurosurgery)

---

## TREATMENT OF CONFIRMED HSV ENCEPHALITIS

---

**First-Line:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Acyclovir** | **10 mg/kg IV q8h** | **14-21 days** |

**Dosing Adjustments:**
- **Renal impairment:** Dose adjust based on CrCl
- **Hemodialysis:** 5-10 mg/kg IV q24h (after dialysis)

**Key Point:** **Complete 14-21 days IV acyclovir** (do NOT switch to oral valacyclovir mid-course - relapse risk)

---

**Monitoring:**
- **Renal function** (acyclovir nephrotoxicity - ensure adequate hydration)
- **Repeat HSV PCR** at end of therapy (if still positive → Extend treatment)
- **Repeat MRI** (assess for complications - edema, hemorrhage)

---

**Relapse:**
- **5-10% relapse rate** (symptoms recur after completing acyclovir)
- **Treatment:** Repeat acyclovir 10 mg/kg IV q8h x 14-21 days

---

## TREATMENT OF OTHER VIRAL ENCEPHALITIS

| **Virus** | **Treatment** | **Duration** |
|-----------|---------------|--------------|
| **HSV-1** | **Acyclovir** 10 mg/kg IV q8h | **14-21 days** |
| **VZV** | **Acyclovir** 10-15 mg/kg IV q8h | **10-14 days** |
| **Enteroviruses** | **Supportive care** (no antiviral) | N/A |
| **Arboviruses** (WNV, EEE, etc.) | **Supportive care** (no antiviral) | N/A |
| **Rabies** | **Palliative care** (no effective treatment once symptomatic) | N/A |
| **CMV** (immunocompromised) | **Ganciclovir** 5 mg/kg IV q12h + **Foscarnet** 60 mg/kg IV q8h | **3-6 weeks** |

**Key Point:** **Only HSV and VZV have effective antiviral therapy** (acyclovir)

---

## SUPPORTIVE CARE

**ICU Management:**
- **Airway protection** (intubation if GCS <8 or refractory seizures)
- **ICP monitoring** (if severe cerebral edema)
- **Seizure management:**
  - **Antiepileptics:** Levetiracetam, valproate, phenytoin
  - **Status epilepticus:** Benzodiazepines, propofol, phenobarbital

**Cerebral Edema Management:**
- **Hypertonic saline** OR **Mannitol**
- **Elevate head of bed 30°**
- **Avoid hyperthermia, hypotension**

**Rehabilitation:**
- **Physical therapy, occupational therapy, speech therapy** (for neurologic sequelae)

---

## PROGNOSIS

**HSV Encephalitis:**
- **Mortality:** 20-30% (with acyclovir; 70% without)
- **Neurologic sequelae:** 50-70% (memory impairment, personality changes, seizures)
- **Predictors of poor outcome:**
  - **Delayed acyclovir initiation** (>48h after symptom onset)
  - **Age >30 years**
  - **GCS <6 at presentation**

**Key Point:** **Early acyclovir improves survival and neurologic outcomes**

---

**Other Viral Encephalitis:**
- **VZV:** 10-20% mortality
- **WNV:** 10% mortality (neuroinvasive disease)
- **EEE:** 30-50% mortality (most severe arboviral encephalitis)
- **Enterovirus:** <5% mortality

---

## AUTOIMMUNE ENCEPHALITIS TREATMENT

**Anti-NMDA Receptor Encephalitis:**

**First-Line:**
- **Remove trigger** (tumor resection if ovarian teratoma)
- **IVIG** 0.4 g/kg/day IV x 5 days
- **OR Methylprednisolone** 1g IV daily x 5 days
- **OR Plasmapheresis** (plasma exchange)

**Second-Line (If Refractory):**
- **Rituximab** (anti-CD20) 375 mg/m² IV weekly x 4 weeks
- **Cyclophosphamide**

**Prognosis:**
- **80% improve** with treatment (but may take months to recover)

---

**Mnemonic: "ACTS for Encephalitis Workup"**
- **A**cyclovir (start immediately)
- **C**SF (HSV PCR, VZV PCR, enterovirus PCR)
- **T**emporal lobe (MRI - HSV predilection)
- **S**eizures (EEG - PLEDs in HSV)

**Mnemonic: "HSV = Hemorrhagic + Seizures + Bizarre behavior"**
- **H**emorrhagic CSF (RBCs)
- **S**eizures (50-70%)
- **V**ery bizarre behavior (temporal lobe dysfunction)

**Mnemonic: "Acyclovir Until Proven Otherwise"**
- **A**cyclovir 10 mg/kg IV q8h
- Start **U**ntil HSV PCR results available
- **P**roven otherwise (HSV PCR negative → Stop)

**Clinical Pearls:**
- **Encephalitis = altered mental status + fever** (required for diagnosis)
- **HSV-1 = #1 sporadic encephalitis** (10-20% of cases), #1 treatable cause
- **Start acyclovir IMMEDIATELY** (10 mg/kg IV q8h) - do NOT wait for HSV PCR
- **MRI temporal lobe involvement = HSV encephalitis** (until proven otherwise)
- **HSV CSF:** Lymphocytic pleocytosis + **RBCs** (hemorrhagic), HSV PCR 95% sensitive
- **HSV PCR may be false negative** if LP <72h after symptom onset (repeat LP if high suspicion)
- **EEG: PLEDs (periodic lateralized epileptiform discharges)** = suggestive of HSV
- **Acyclovir 14-21 days** (complete full IV course, do NOT switch to oral mid-treatment)
- **Untreated HSV encephalitis mortality 70%** → Treated 20-30%
- **Early acyclovir improves outcomes** (start within 48h)
- **Neurologic sequelae 50-70%** despite treatment (memory, personality, seizures)
- **VZV encephalitis may occur WITHOUT rash** (zoster sine herpete)
- **West Nile Virus = #1 arboviral encephalitis** in US (acute flaccid paralysis)
- **Rabies = 100% fatal** once symptomatic (hydrophobia, aerophobia)
- **Anti-NMDA encephalitis:** Young women, ovarian teratoma, psychiatric symptoms → Seizures → Movement disorder

**Media:** None

**Sources:** [IDSA 2008 - Encephalitis Guidelines], [Lancet Neurology 2024 - HSV encephalitis], [NEJM 2023 - Viral encephalitis], [Brain 2024 - Autoimmune encephalitis], [CDC 2024 - Arboviral encephalitis surveillance]
